ST
CLDX icon

Stifel Trust’s Celldex Therapeutics CLDX Stock Holding History

Stifel Trust’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$165K Buy
847
+67
+9% +$14.6K 0.03% 191
2014
Q2 		$191K Buy
780
+20
+3% +$4.52K 0.04% 182
2014
Q1 		$202K Sell
760
-472
-38% -$181K 0.04% 178
2013
Q4 		$448K Buy
1,232
+99
+9% +$38.1K 0.08% 141
2013
Q3 		$603K Buy
1,133
+133
+13% +$45.6K 0.12% 131
2013
Q2 		$235K Buy
+1,000
New +$197K 0.05% 167

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Stifel Trust's CLDX Position: Q3 2014 in Review

Stifel Trust increased its Celldex Therapeutics (CLDX) stake by 8.6% in Q3 2014, buying an estimated $14.6K and bringing the position to 847 shares worth $165K. The position accounts for 0.03% of the portfolio, ranked #191.

Stifel Trust first reported a position in CLDX in Q2 2013 and has held it in 6 quarters since. The position peaked at $603K in Q3 2013. 148 funds tracked by Wall St. Rank hold CLDX as of Q3 2014.

  • Stifel Trust held 847 shares of Celldex Therapeutics worth $165K as of Q3 2014.
  • Stifel Trust bought 67 Celldex Therapeutics shares in Q3 2014, an estimated $14.6K.
  • Celldex Therapeutics made up 0.03% of Stifel Trust's portfolio in Q3 2014, its #191 holding.
  • Stifel Trust first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 6 quarters since.
  • Stifel Trust's Celldex Therapeutics position peaked at $603K in Q3 2013.
  • 148 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2014.

Based on Stifel Trust's 13F filing for Q3 2014, filed 14 Nov 2014.